<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20340" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HIV Neurocognitive Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mitra</surname>
            <given-names>Paroma</given-names>
          </name>
          <aff>New York University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharman</surname>
            <given-names>Tariq</given-names>
          </name>
          <aff>Southern Ohio Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Paroma Mitra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tariq Sharman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20340.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Patients with human immunodeficiency virus infection (HIV infection) have been noted to have various forms of neuropsychiatric illnesses. These include symptoms of both cognitive disorders as well as mood and anxiety symptoms. This activity reviews the epidemiology, etiology, clinical signs and symptoms, evaluation, and treatment of neurocognitive disorder secondary to HIV disease and highlights the interprofessional team's role in evaluating and treating this condition. This activity also reviews basic screening tools for the disease and evidence-based treatment guidelines. This activity also covers a section on current research studies on neurocognitive disorders secondary to HIV.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the impact of HIV disease on major cognitive disorders or dementia.</p></list-item><list-item><p>Identify the different stages of dementia or neurocognitive disorder secondary to HIV disease.</p></list-item><list-item><p>Outline the management options available for dementia or neurocognitive disorder secondary to HIV disease.</p></list-item><list-item><p>Describe the importance of improving care coordination amongst interprofessional team members to improve outcomes for patients affected by neurocognitive disorders secondary to HIV disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20340&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20340">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20340.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Patients with human immunodeficiency virus (HIV) infection have been noted to have various forms of neuropsychiatric illnesses. Neuropsychiatric illnesses include symptoms of both cognitive disorders as well as mood and anxiety symptoms.<xref ref-type="bibr" rid="article-20340.r1">[1]</xref> In the past, before the advent of antiretroviral treatment, several neuropsychiatric disorders remained untreated, resulting in significant morbidity and mortality for these patients.<xref ref-type="bibr" rid="article-20340.r2">[2]</xref> Most of these disorders stemmed from untreated infectious diseases secondary to acquired AIDS (acquired immunodeficiency syndrome), like toxoplasmosis and encephalitis.<xref ref-type="bibr" rid="article-20340.r3">[3]</xref> The decline in neurocognitive disorders notably came hand in hand with the advent of HAART (highly active antiretroviral therapy). Combination treatment for HIV was developed around 1996, and since then, the incidence of HIV-related neuropsychiatric disorders has started to decline.<xref ref-type="bibr" rid="article-20340.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>Frascati Classification of HIV-associated Neurocognitive Disorders</bold>
</p>
        <p>The United States National Institutes of Health published a classification scheme in 2007 to define these neuropsychiatric disorders so that there may be uniformity in clinical assessments and research for these disorders. This classification system is called the "Frascati criteria," although it has not been universally adopted.<xref ref-type="bibr" rid="article-20340.r5">[5]</xref>&#x000a0;This classification can only be applied when neurocognitive impairment cannot be explained by any other condition (other than HIV). Opportunistic infections, malignancy, stroke, substance use with toxicity or withdrawal syndromes, or acute encephalopathy must be excluded before this classification is applied or considered.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Asymptomatic neurocognitive impairment: When the individual scores 1 standard deviation (SD) or more below the mean in 2 or more cognitive domains on standardized neuropsychological testing. There is usually no overt functional impairment.</p>
          </list-item>
          <list-item>
            <p>Mild neurocognitive disorder: When the individual scores 1&#x000a0; SD or more below the mean in 2 or more cognitive domains on standardized neuropsychological testing AND has evidence of overt (usually mild) functional impairment.</p>
          </list-item>
          <list-item>
            <p>HIV-associated dementia: When the individual scores 2 SD or more below the mean in 2 or more cognitive domains on standardized neuropsychological testing AND has evidence of functional impairment affecting activities of daily living.</p>
          </list-item>
        </list>
        <p>As the above definitions clearly indicate, applying these criteria requires formalized testing and should not be done without objective evaluation.&#x000a0;</p>
      </sec>
      <sec id="article-20340.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HIV directly crosses the blood-brain barrier during the acute phase of infection. However, it is during the chronic inflammation phase that cognitive changes are seen. Monocytes, macrophages, and white matter are all affected in the brain.<xref ref-type="bibr" rid="article-20340.r6">[6]</xref> HIV reproduces in the microglia, which are known as the brain's "immune cells." These changes are associated with clinical signs and symptoms of neurocognitive disorders seen with HIV disease. However, not all patients with HIV will develop these disorders. A number of different risk factors have been identified and are discussed below.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Low nadir CD4 count: Results from several studies have shown that the severity of HIV disease, which is extrapolated from a low nadir CD4 count, correlates with the risk of developing neurocognitive disorders.<xref ref-type="bibr" rid="article-20340.r7">[7]</xref><xref ref-type="bibr" rid="article-20340.r8">[8]</xref>&#x000a0;Another study reported an increased risk for HIV-associated dementia in patients with a longer duration of HIV infection and the presence of AIDS-defining lesions with a low CD4 count (defined as less than 200 cells/mm3).<xref ref-type="bibr" rid="article-20340.r9">[9]</xref>&#x000a0;These studies suggested a sustained impairment with a non-reversible component of neurocognitive dysfunction in these patients.<xref ref-type="bibr" rid="article-20340.r7">[7]</xref>&#x000a0;The studies observed a lack of association between neurocognitive impairment and improvement in laboratory parameters following HAART therapy, suggesting that neural injury secondary to HIV does not improve despite antiretroviral therapy.<xref ref-type="bibr" rid="article-20340.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Advanced age: Although there is an increased prevalence of neurocognitive disorders in patients with HIV who are 50 years or older, it is unclear if this is due to a direct result of HIV infection versus advanced age itself.<xref ref-type="bibr" rid="article-20340.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Coexistent cardiovascular disease and obesity: There is a higher risk of dementia in patients with cardiovascular risk factors and underlying cardiovascular disease and HIV infection when compared to the general population.<xref ref-type="bibr" rid="article-20340.r11">[11]</xref>&#x000a0;These comorbidities have a higher correlation with the development of neurocognitive disorders in patients with HIV than HIV viral load or CD4 cell counts.<xref ref-type="bibr" rid="article-20340.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Coinfection with hepatitis C: There is conflicting data regarding the risk of hepatitis C coinfection in patients with HIV when determining the risk of neurocognitive disorders. Some studies identify clear risk when both infections are present,<xref ref-type="bibr" rid="article-20340.r13">[13]</xref>&#x000a0;but some study results report no evidence of increased neurocognitive impairment in patients coinfected with the two viruses.<xref ref-type="bibr" rid="article-20340.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>History of toxoplasmosis: A prior history of toxoplasma infection has been associated with an increased risk of neurocognitive deficits, especially in patients with latent toxoplasma infections. This risk was observed independent of CD4 cell counts.<xref ref-type="bibr" rid="article-20340.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>Interestingly, despite multiple studies attempting to identify genetic predisposition for the development of HIV-associated neurocognitive disorder, there is no evidence to support any particular mutation. A large multicenter trial evaluating more than 1200 patients did not detect an association between any polymorphisms and HIV-associated neurocognitive disorders.<xref ref-type="bibr" rid="article-20340.r16">[16]</xref></p>
      </sec>
      <sec id="article-20340.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The initial epidemiological data on HIV-associated dementia identified this disorder as a common occurrence in patients with HIV, affecting as many as 40% of the patients infected with HIV.<xref ref-type="bibr" rid="article-20340.r17">[17]</xref>&#x000a0;These disorders were collectively termed "AIDS dementia complex" when they were first identified.<xref ref-type="bibr" rid="article-20340.r18">[18]</xref>&#x000a0;In the United States, approximately 50% of the patients with HIV were noted to have a cognitive impairment when studies were first conducted.<xref ref-type="bibr" rid="article-20340.r8">[8]</xref>&#x000a0;With the advent of antiretroviral therapy, the prevalence of these disorders has declined, especially in people who are on treatment consistently.<xref ref-type="bibr" rid="article-20340.r19">[19]</xref><xref ref-type="bibr" rid="article-20340.r20">[20]</xref>&#x000a0;Data from the CASCADE cohort revealed a decrease in the incidence of these disorders&#x000a0;from 6.49 per 1000 person-years to 0.66 per 1000 person-years.<xref ref-type="bibr" rid="article-20340.r9">[9]</xref>&#x000a0;Despite the decline in severe neurocognitive deficits, there is a substantial prevalence of mild cognitive impairment despite viral suppression.<xref ref-type="bibr" rid="article-20340.r21">[21]</xref>&#x000a0;Recent studies in the post-HAART era report&#x000a0;asymptomatic neurocognitive impairment (ANI) as the most common neurocognitive disorder, with a prevalence of 33%. Mild neurocognitive disorder was reported to have a prevalence of 12%, and HIV-associated dementia was noted to be present in only 2% of the cases.<xref ref-type="bibr" rid="article-20340.r8">[8]</xref>&#x000a0;There is recent debate regarding the cause of persistent neurocognitive deficits in the post-HAART era. While some studies continue to outline the increased risk of neurocognitive disorders in patients with HIV,<xref ref-type="bibr" rid="article-20340.r22">[22]</xref>&#x000a0;other studies have reported no difference in the prevalence of these disorders among patients with HIV (who were able to achieve viral suppression with adequate CD4 cell counts) and age-matched controls who did not have HIV.<xref ref-type="bibr" rid="article-20340.r23">[23]</xref></p>
      </sec>
      <sec id="article-20340.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>HIV crosses the blood-brain barrier and infiltrates the macrophages in the central nervous system. A virus-induced fusion of macrophages leads to the formation of giant cells and astrocyte activation and damage (astrocytes are cells that provide metabolic support and detoxify neurons), ultimately leading to neuronal damage in many parts of the brain. The damage is caused by verotoxins, including HIV proteins gp41, gp120, Tat, Vpr, Nef, and Rev. The subcortical structures are most affected, like the limbic structures and basal ganglia.<xref ref-type="bibr" rid="article-20340.r24">[24]</xref> HIV infection also causes a breakdown of white matter and axonal damage.<xref ref-type="bibr" rid="article-20340.r25">[25]</xref>&#x000a0;Ultimately, this leads to a decline in cognition and, notably, a decreased volume of the brain structures like basal ganglia and caudate nucleus, causing atrophy of the brain volume.<xref ref-type="bibr" rid="article-20340.r26">[26]</xref>&#x000a0;Autopsy studies of patients with AIDS and HIV-associated dementia revealed white matter pallor, microglial nodules, multinucleated giant cells, and perivascular infiltrates.<xref ref-type="bibr" rid="article-20340.r27">[27]</xref></p>
      </sec>
      <sec id="article-20340.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In the pre-HAART era, when the incidence of HIV-associated dementia was considerably high, brain autopsies showed meningitis with low counts of lymphocytes and perivascular lymphocytic cuffing.<xref ref-type="bibr" rid="article-20340.r28">[28]</xref>&#x000a0;The cells that are seen are generally CD8 T- lymphocytes and CD4 lymphocytes.<xref ref-type="bibr" rid="article-20340.r29">[29]</xref>&#x000a0;HIV&#x000a0;enters the brain via HIV-infected lymphocytes and macrophages. This is in addition to the passage of cell-free virus into the brain and the release of the virus from the infected endothelial cells.&#x000a0;The virus replicates in these cells and infects the microglia,&#x000a0;astrocytes,&#x000a0;oligodendrocytes, and neurons. HIV infection in the central nervous system can be detected and monitored by cerebrospinal fluid (CSF) viral load measurements. Another&#x000a0;pathological feature in HIV-associated encephalitis is the presence of multinucleated giant cells, which was very prominent before the advent of antiretroviral drugs.<xref ref-type="bibr" rid="article-20340.r30">[30]</xref>&#x000a0;Multiple studies established a positive correlation between CSF viral load and the extent of cognitive dysfunction.</p>
      </sec>
      <sec id="article-20340.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The earliest symptoms and signs are impairment in concentration, memory, and executive functioning. As the disease progresses, psychomotor retardation, depressive symptoms, irritability, and subclinical motor signs are observed. These motor signs include tremors and hyperreflexia. With time and continued progression, the clinical features evolve to include overall global dementia, myelopathy, neuropathy, and even Parkinson-like features.<xref ref-type="bibr" rid="article-20340.r31">[31]</xref>&#x000a0;The severity of HIV infection and antiretroviral treatment (ART) status greatly affects the presentation of HIV-associated neurocognitive disorders (HAND). As described above, patients with severe disease (dementia) are likely to have untreated HIV infection with low CD4 cell counts. They are likely not on any ART or are on ineffective regimens. Patients on ART are likely to have a slowly progressive course of neurocognitive decline with milder deficits.&#x000a0;When present,&#x000a0;HIV-associated dementia classically presents with subcortical dysfunction. This usually constitutes attention-concentration impairment, depressive symptoms, and impaired psychomotor functions.<xref ref-type="bibr" rid="article-20340.r18">[18]</xref><xref ref-type="bibr" rid="article-20340.r32">[32]</xref>&#x000a0;Cognitive deficits manifest as memory impairment,&#x000a0;impaired executive functioning, and apathy.<xref ref-type="bibr" rid="article-20340.r33">[33]</xref>&#x000a0;In mild neurocognitive decline, impaired attention and working memory are the predominant features. Higher executive functioning may also be impaired. These deficits may not necessarily be clinically evident. When symptomatic, they may reveal difficulty with reading and/or maintaining concentration in conversations or activities.<xref ref-type="bibr" rid="article-20340.r34">[34]</xref>&#x000a0;Motor dysfunction is usually absent in mild forms without dementia.&#x000a0;</p>
        <p>
<bold>CNS Viral Escape Syndrome</bold>
</p>
        <p>This is a very uncommon but clinically recognized condition and can be seen in patients who are receiving antiretroviral therapy and present with severe new-onset neurological deficits. A "viral escape" phenomenon occurs when the patient has adequate peripheral viral suppression, but there is evidence of CNS HIV replication.<xref ref-type="bibr" rid="article-20340.r35">[35]</xref> In most cases with this condition, there is also drug resistance in the CSF HIV viral strain. It is imperative to note that not all patients with evidence of CSF HIV viral replication will go on to develop this disease.&#x000a0;Detectable CSF HIV ribonucleic acid (RNA) can be observed in patients without any evidence of neurocognitive dysfunction.<xref ref-type="bibr" rid="article-20340.r36">[36]</xref>&#x000a0;In patients suspected of presenting with CNS viral escape syndrome,&#x000a0;CSF analysis for HIV RNA level and genotype testing is warranted to diagnose CNS viral escape and change the antiretroviral regimen to effective regimens if indicated based on resistance patterns.&#x000a0;</p>
        <p>
<bold>Immune Reconstitution Inflammatory Syndrome </bold>
</p>
        <p>Another rare cause of new-onset neurocognitive symptoms in patients with HIV is immune reconstitution inflammatory syndrome (IRIS). This is due to HIV CNS infection and presents with severe encephalitis, diffuse white and gray matter abnormalities on radiographic imaging, and CD8 cell pleocytosis in the CSF.<xref ref-type="bibr" rid="article-20340.r37">[37]</xref></p>
      </sec>
      <sec id="article-20340.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The main tool for evaluation is neuropsychological testing. Some neuropsychological testing domains that have shown impairment include episodic memory (learning and recall), executive functions, attention/working memory, information processing, verbal fluency, and fine motor skills.<xref ref-type="bibr" rid="article-20340.r31">[31]</xref><xref ref-type="bibr" rid="article-20340.r38">[38]</xref> Some other aspects of neurocognitive testing include trail making test (to test executive functioning), the use of a grooved keyboard (to test for psychomotor skills), a digit span test (to determine psychomotor speed, abstraction, memory, and attention), and also the use of the Stroop test (test attention and processing speed).<xref ref-type="bibr" rid="article-20340.r39">[39]</xref>&#x000a0;Another form of evaluation is the use of imaging. In the pre-HIV treatment era, imaging was significant for global brain atrophy. HIV-related encephalitis can be evaluated with FLAIR imaging, which will show focal atrophy in the basal ganglia, thalamus, corpus callosum, and frontal lobes.<xref ref-type="bibr" rid="article-20340.r40">[40]</xref> Recently, 3D imaging has studied the patterns of brain atrophy to correlate with ongoing cognitive impairment. Specific areas included sensorimotor areas, parts of the corpus callosum, and parts of the frontal lobes.<xref ref-type="bibr" rid="article-20340.r41">[41]</xref> Many new imaging studies have compared infected individuals to normal same-age controls. Hence, the correlation between cognitive decline in infected individuals and relevant brain areas is now well established.</p>
        <p>A good screening tool is the International HIV Dementia Scale, which tests memory, motor speed, and psychomotor speed. The test includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Memory registration is tested by giving a patient 4 words and asking them to repeat them. Then, the patient is requested to retain the words.</p>
          </list-item>
          <list-item>
            <p>Motor speed is tested by having the patient tap the first 2 fingers of their non-dominant hand as quickly as possible. The number of taps in 5 seconds is counted.</p>
          </list-item>
          <list-item>
            <p>Psychomotor speed is measured by having the patient use their non-dominant hand to do a series of tasks, such as clenching their fist, placing the palm face down, and then placing it perpendicularly on the table. The speed and sequence are measured.</p>
          </list-item>
          <list-item>
            <p>The patient is asked to recall the four words practiced earlier.<xref ref-type="bibr" rid="article-20340.r42">[42]</xref></p>
          </list-item>
        </list>
        <p>Another screening tool is the modified HIV scale, which tests immediate memory and delayed recall. Immediate and delayed memory is tested by asking patients to register 4 words and then asking them to repeat the words a few minutes later. Executive functioning is tested by copying a cube. Psychomotor speed is tested by asking the patient to write the alphabet in capital letters.<xref ref-type="bibr" rid="article-20340.r43">[43]</xref>&#x000a0;Results from one study showed that clinically, three simple questions might be a good screening tool for HIV-associated neurocognitive disorder; these include asking whether patients experience memory loss, have difficulty paying attention, and feel slower while reasoning or doing complicated tasks.<xref ref-type="bibr" rid="article-20340.r44">[44]</xref>&#x000a0;However, the mainstay for evaluation is still getting a good clinical history and collaborative information about the start of cognitive decline. This is highly recommended by the Mind Exchange Program, which is established by expert clinicians around the&#x000a0;world.<xref ref-type="bibr" rid="article-20340.r45">[45]</xref></p>
      </sec>
      <sec id="article-20340.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment with antiretroviral drugs (HAART) has shown improvement in cognitive function, including all cognitive domains. Also, the increase in CD4 count and the decrease in viral load have been correlated with cognitive improvement.<xref ref-type="bibr" rid="article-20340.r46">[46]</xref>&#x000a0;The treatment, therefore, revolves around the adequate treatment of HIV to achieve viral suppression and adequate CD4 counts. Some experts believe the drug's ability to cross the blood-brain barrier and achieve a high concentration in the cerebrovascular fluid is essential to lower the viral load. Letendre S et al studied the CNS penetrability of ARV drugs. Individual anti-retroviral (ARV) drugs were assigned a penetration rank of 0 (low), 0.5 (intermediate), or 1 (high). This ranking system was based on drug concentration in CSF, chemical properties, and CNS effectiveness in clinical studies. The CNS penetration-effectiveness (CPE) was calculated by summing the individual penetration ranks for each ARV in the regimen.<xref ref-type="bibr" rid="article-20340.r47">[47]</xref> For example, combinations of efavirenz, lamivudine, and zidovudine have high CPE. Drugs like abacavir have a lower CPE score. Lower CPE ranks correlated with higher CSF viral load in their analysis.<xref ref-type="bibr" rid="article-20340.r48">[48]</xref> A small study that included 37 people showed greater cognitive improvement with greater penetrability of the drug.<xref ref-type="bibr" rid="article-20340.r49">[49]</xref>&#x000a0;Another study looked at patients with HIV &#x000a0;with cognitive impairment and patients with cognitive impairment without HIV, and it showed a worsening in cognitive scores. The theory is that ARV drugs with high penetrability can be neurotoxic, too. So, it is suggested to suspect ARV neurotoxicity when cognitive improvement is not seen with antiretroviral treatment.<xref ref-type="bibr" rid="article-20340.r50">[50]</xref></p>
        <p>Despite the above data, there is no clear evidence that certain regimens are more effective than others for neurocognitive disorders of HIV. Expert opinion suggests that antiretroviral agents with a "CNS penetration effectiveness (CPE)" score based on CSF drug kinetics might be better suited for these patients. However, clinical data to support this practice is lacking.<xref ref-type="bibr" rid="article-20340.r51">[51]</xref>&#x000a0;Observational studies evaluating CPE to guide regimen selection have provided conflicting data; one study reported that ART regimens with a high CPE score were associated with greater improvements in concentration and mental flexibility<xref ref-type="bibr" rid="article-20340.r52">[52]</xref>,&#x000a0;but another study reported a small yet opposite effect.<xref ref-type="bibr" rid="article-20340.r48">[48]</xref></p>
        <p>In general, however, it is important to avoid efavirenz in patients with HIV-associated&#x000a0;neurocognitive impairment. This is not due to its CPE score but due to the risk of neuropsychiatric side effects associated with this medication. Most research articles emphasize the use of psychiatric medications as needed for mood disorders. Many subtypes of antidepressants have been studied, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors. All of these showed moderate symptomatic relief.<xref ref-type="bibr" rid="article-20340.r53">[53]</xref><xref ref-type="bibr" rid="article-20340.r54">[54]</xref> Psychostimulants may also be used for fatigue and apathy.<xref ref-type="bibr" rid="article-20340.r55">[55]</xref> Psychotic and manic symptoms are less studied in those who are HIV-positive; however, research was done on a small sample with psychosis and has shown a greater incidence of extrapyramidal symptoms.<xref ref-type="bibr" rid="article-20340.r56">[56]</xref> Some mood stabilizers like lithium have concurrent neurotoxic effects. Some medications, like carbamazepine, can induce the same cytochrome P 450 (CYP) enzyme system as many of the antiretroviral drugs and cause drug interactions.<xref ref-type="bibr" rid="article-20340.r57">[57]</xref><xref ref-type="bibr" rid="article-20340.r58">[58]</xref>&#x000a0;In theory, several drugs are considered neuroprotective, such as memantine, pentoxifylline, selegiline, nimodipine, and peptide T. However, only selegiline has shown efficacy.<xref ref-type="bibr" rid="article-20340.r59">[59]</xref></p>
      </sec>
      <sec id="article-20340.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses include primary neurocognitive disorder and its subtypes.&#x000a0;Given that persons with HIV have increased longevity, the primary neurocognitive disorder may also set in. Often, it becomes progressively more difficult to differentiate between neurocognitive disorder secondary to HIV and primary neurocognitive disorder.<xref ref-type="bibr" rid="article-20340.r60">[60]</xref> Another differential diagnosis is major depressive disorder, which can present with signs and symptoms of pseudodementia. Some common features also include psychomotor retardation and lack of concentration. The prevalence of Major Depressive Disorder is higher in persons with HIV. Some symptoms remain in common, including apathy rather than a lack of interest in other activities. There is an increased incidence of dysphoria in both entities.<xref ref-type="bibr" rid="article-20340.r61">[61]</xref><xref ref-type="bibr" rid="article-20340.r62">[62]</xref>&#x000a0;Other differentials include substance intoxication and withdrawal, metabolic disorders, opportunistic infections (CNS toxoplasmosis, cryptococcal meningitis), brain tumors, traumatic brain injury, and even adverse effects of antiretroviral medications like efavirenz.<xref ref-type="bibr" rid="article-20340.r63">[63]</xref></p>
        <p>The following conditions are important to remember in the differential diagnosis when considering possible HIV-associated dementia:</p>
        <p>
<bold>Central Nervous System Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CNS lymphoma</p>
          </list-item>
          <list-item>
            <p>CNS&#x000a0;toxoplasmosis</p>
          </list-item>
          <list-item>
            <p>CNS vasculitis</p>
          </list-item>
          <list-item>
            <p>Cryptococcal meningitis</p>
          </list-item>
          <list-item>
            <p>Cytomegalovirus encephalitis</p>
          </list-item>
          <list-item>
            <p>Metastatic disease</p>
          </list-item>
          <list-item>
            <p>Neurosyphilis</p>
          </list-item>
          <list-item>
            <p>Progressive multifocal leukoencephalopathy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tuberculous meningitis</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Substance Withdrawal or Intoxication</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Alcohol</p>
          </list-item>
          <list-item>
            <p>Chronic cannabis</p>
          </list-item>
          <list-item>
            <p>Opioids</p>
          </list-item>
        </list>
        <p>
<bold>Metabolic and Endocrine Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Addison disease</p>
          </list-item>
          <list-item>
            <p>B12 deficiency</p>
          </list-item>
          <list-item>
            <p>Thyroid disease&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Psychiatric Illness</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Delirium</p>
          </list-item>
          <list-item>
            <p>Mood disorders (major depression, dysthymia)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20340.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>The longitudinal CHARTER study is one of the most prominent clinical research studies that focus on neurocognitive deficits in persons with HIV. It investigated the incidence and predictors of neurocognitive change over 16&#x000a0;to 72 months (mean 35) in 436 HIV-infected participants in the CNS HIV Anti-Retroviral Therapy Effects Research cohort. The conclusion was that neurocognitive changes were complex and depended on several factors, including HIV treatment and the extent of HIV infection and comorbid infections.<xref ref-type="bibr" rid="article-20340.r64">[64]</xref>&#x000a0;In a study of the Use of Nonantiretroviral Medications That May Impact Neurocognition, 3300 women (71% with HIV) and data from almost 42,000 visits were studied. HIV infection was associated with neurocognitive adverse effects (NC-AE) medication use, which may influence the determinations of HIV-associated neurocognitive impairment. So, it is advised that physicians consider the impact of NC-AE medications when evaluating patients with HIV and concurrent neurocognitive symptoms.<xref ref-type="bibr" rid="article-20340.r65">[65]</xref></p>
      </sec>
      <sec id="article-20340.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>According to the MIND exchange working group, there have been no studies that discuss the prognosis of HIV-associated neurocognitive disorder (HAND), however markers of HIV disease (low CD4 count and high viral load), ongoing poor scores on neuropsychological testing, and concurrent mood disorder all point towards a poor prognosis.<xref ref-type="bibr" rid="article-20340.r45">[45]</xref></p>
      </sec>
      <sec id="article-20340.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of HIV dementia, as mentioned above, can also include comorbid mood and anxiety disorders. Research has shown that chronic stress can lead to a weakened immune system and increase the risk of other diseases.<xref ref-type="bibr" rid="article-20340.r66">[66]</xref> Also, given the longevity of persons living with HIV now, other forms of dementia, including primary neurocognitive illness, have become a comorbid complication.<xref ref-type="bibr" rid="article-20340.r67">[67]</xref></p>
      </sec>
      <sec id="article-20340.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is primarily around early diagnosis and treatment of the disease. Treatment with HAART can delay and even deter the onset of dementia secondary to HIV disease. High viral loads and low CD4 cell counts are associated with a higher incidence of HIV-associated dementia; therefore, early HAART therapy is paramount in the prevention of severe neurocognitive decline in patients with HIV. Screening asymptomatic patients with HIV for neurocognitive impairment is somewhat controversial. Arguments against this practice namely highlight cost-effectiveness and the limited resources in most settings to screen asymptomatic patients for this disease. However, some studies suggest that screening asymptomatic patients can lead to early recognition and allow a change in HAART regimens to those that optimally penetrate the central nervous system, which in turn will improve clinical outcomes.<xref ref-type="bibr" rid="article-20340.r68">[68]</xref></p>
      </sec>
      <sec id="article-20340.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Consensus Guidelines from the Mind Exchange Working Group</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>All patients with HIV should be assessed for neurocognitive functioning regardless of apparent symptoms or CD4/HIV viral load.</p>
          </list-item>
          <list-item>
            <p>Reassessment should occur every 6 to 12 months in patients who are at high-risk or every 12 to 24 months in low-risk patients.</p>
          </list-item>
          <list-item>
            <p>Comprehensive neurocognitive evaluation includes the evaluation of at least 5 neurocognitive domains (verbal/language, attention/working memory, abstraction/executive function, learning/recall, speed of information processing, and motor skills).</p>
          </list-item>
          <list-item>
            <p>Any standardized and validated screening/evaluation tool is acceptable, as no particular instrument has been shown to be of superior performance for the detection of this disorder.</p>
          </list-item>
          <list-item>
            <p>There is no data to support any preventive measures for this disease other than adequate treatment of HIV infection.</p>
          </list-item>
          <list-item>
            <p>Combination anti-retroviral therapy (ART) for 1 year has been shown to have modest benefits in neuropsychological functioning.</p>
          </list-item>
          <list-item>
            <p>This improved neurologic function was most apparent in attention, processing speed, and executive performance.</p>
          </list-item>
          <list-item>
            <p>Treatment regimens based on&#x000a0;CNS penetration scores have not been consistently associated with improved neurologic functioning; therefore,&#x000a0;changing ART to improve CNS penetration for patients whose infection is already well controlled is unwarranted.</p>
          </list-item>
          <list-item>
            <p>No therapy other than effective combination ART therapy is recommended for the treatment of this disease. Minocycline, memantine, selegiline, lithium, valproic acid, lexipafant, and nimodipine have been evaluated, but their effectiveness has not been proven.<xref ref-type="bibr" rid="article-20340.r45">[45]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20340.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The mainstay of treatment lies in early detection. All providers who encounter patients with HIV disease should be encouraged to start their patients on HAART. Patients must receive education about the onset of HIV-associated dementia, especially early signs of asymptomatic neurocognitive impairment, which may show a decrease in functioning. All providers must also be educated about the stages of dementia, especially when patients speak about the gradual loss of functioning in daily activities. Infectious disease specialists treating these patients are encouraged to perform simple screening tests like the Mini-Mental State Exam or the Montreal Cognitive Assessments to look for neurocognitive impairment. They are also encouraged to simultaneously screen for symptoms of depression, including anhedonia, apathy, and lack of concentration. If there is any deficit seen in the screening tests, providers are highly encouraged to refer the patients for neuropsychological testing to determine areas of dysfunction.</p>
        <p>Given that mood symptoms are prevalent in patients with HIV disease, a careful history&#x000a0;is necessary regarding the onset of mood symptoms, and screeners such as the PHQ-9 may be used. If a patient scores in the range of moderate to severe depression, then a referral to a mental health provider should be made. Evidence has shown that treatment of concurrent mood and even psychotic symptoms has played a role in treating HIV-associated neurocognitive disorders. In case patients with HIV disease are hospitalized and show signs of cognitive dysfunction, a careful distinction must be made between delirium and cognitive decline. Longitudinal cognitive assessments and neurological exams must be made during the hospitalization. Specialty-trained nurses can assist clinicians with early detection of this disease by conducting a cognitive screen every year and monitoring scores to recognize any sharp decline. Nurses can also help&#x000a0;educate patients regarding the importance of compliance with HAART to prevent this disease. Clinical pharmacists can help providers identify treatment options with minimal adverse side effects and check for drug-drug interactions. A collaborative interprofessional team approach to patients with HIV can help deter neurocognitive disorders and ensure adequate management if the disease occurs.</p>
      </sec>
      <sec id="article-20340.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20340&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20340">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hiv-neurocognitive-disorders/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20340">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20340/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20340">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20340.s18">
        <title>References</title>
        <ref id="article-20340.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whetten</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reif</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whetten</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murphy-McMillan</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Trauma, mental health, distrust, and stigma among HIV-positive persons: implications for effective care.</article-title>
            <source>Psychosom Med</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>531</fpage>
            <page-range>531-8</page-range>
            <pub-id pub-id-type="pmid">18541904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snider</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Metroka</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients.</article-title>
            <source>Ann Neurol</source>
            <year>1983</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-18</page-range>
            <pub-id pub-id-type="pmid">6314874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bredesen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Rosenblum</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. 1985.</article-title>
            <source>J Neurosurg</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>107</volume>
            <issue>6</issue>
            <fpage>1253</fpage>
            <page-range>1253-73; discussion 1251</page-range>
            <pub-id pub-id-type="pmid">18077970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michaels</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kissinger</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.</article-title>
            <source>N Engl J Med</source>
            <year>1998</year>
            <month>Aug</month>
            <day>06</day>
            <volume>339</volume>
            <issue>6</issue>
            <fpage>405</fpage>
            <page-range>405-6</page-range>
            <pub-id pub-id-type="pmid">9696654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gissl&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?</article-title>
            <source>BMC Infect Dis</source>
            <year>2011</year>
            <month>Dec</month>
            <day>28</day>
            <volume>11</volume>
            <fpage>356</fpage>
            <pub-id pub-id-type="pmid">22204557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated neurocognitive disorder.</article-title>
            <source>Curr Opin Infect Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-122</page-range>
            <pub-id pub-id-type="pmid">27798498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Smurzynski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>The prevalence and incidence of neurocognitive impairment in the HAART era.</article-title>
            <source>AIDS</source>
            <year>2007</year>
            <month>Sep</month>
            <day>12</day>
            <volume>21</volume>
            <issue>14</issue>
            <fpage>1915</fpage>
            <page-range>1915-21</page-range>
            <pub-id pub-id-type="pmid">17721099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Ake</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Rivera-Mindt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vigil</surname>
                <given-names>OR</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gamst</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fennema-Notestine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jernigan</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Dec</month>
            <day>07</day>
            <volume>75</volume>
            <issue>23</issue>
            <fpage>2087</fpage>
            <page-range>2087-96</page-range>
            <pub-id pub-id-type="pmid">21135382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhaskaran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mussini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antinori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Dorrucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sabin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>K</given-names>
              </name>
              <collab>CASCADE Collaboration</collab>
            </person-group>
            <article-title>Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.</article-title>
            <source>Ann Neurol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-21</page-range>
            <pub-id pub-id-type="pmid">17894380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Skolasky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Selnes</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Watters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poff</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shiramizu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shikuma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valcour</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals.</article-title>
            <source>J Neurovirol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-9</page-range>
            <pub-id pub-id-type="pmid">17613710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Marquie-Beck</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fitzsimons</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Wolfson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rosario</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ances</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Feb</month>
            <day>14</day>
            <volume>78</volume>
            <issue>7</issue>
            <fpage>485</fpage>
            <page-range>485-92</page-range>
            <pub-id pub-id-type="pmid">22330412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moulignier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costagliola</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders.</article-title>
            <source>Curr Top Behav Neurosci</source>
            <year>2021</year>
            <volume>50</volume>
            <fpage>367</fpage>
            <page-range>367-399</page-range>
            <pub-id pub-id-type="pmid">31989463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paulino</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rockenstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Adame</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cherner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Everall</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Masliah</surname>
                <given-names>E</given-names>
              </name>
              <collab>HIV Neurobehavioral Research Center Group</collab>
            </person-group>
            <article-title>Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV.</article-title>
            <source>J Infect Dis</source>
            <year>2007</year>
            <month>Aug</month>
            <day>01</day>
            <volume>196</volume>
            <issue>3</issue>
            <fpage>361</fpage>
            <page-range>361-70</page-range>
            <pub-id pub-id-type="pmid">17597450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Jan</month>
            <day>20</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-50</page-range>
            <pub-id pub-id-type="pmid">25503616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bharti</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Cherner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Dec</month>
            <day>15</day>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>1655</fpage>
            <page-range>1655-1660</page-range>
            <pub-id pub-id-type="pmid">27794019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Service</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Shapshak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Freimer</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.</article-title>
            <source>Am J Med Genet B Neuropsychiatr Genet</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>159B</volume>
            <issue>6</issue>
            <fpage>669</fpage>
            <page-range>669-83</page-range>
            <pub-id pub-id-type="pmid">22628157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navia</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection.</article-title>
            <source>Arch Neurol</source>
            <year>1987</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-9</page-range>
            <pub-id pub-id-type="pmid">3800724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navia</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The AIDS dementia complex: I. Clinical features.</article-title>
            <source>Ann Neurol</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>517</fpage>
            <page-range>517-24</page-range>
            <pub-id pub-id-type="pmid">3729308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watkins</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Treisman</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Cognitive impairment in patients with AIDS - prevalence and severity.</article-title>
            <source>HIV AIDS (Auckl)</source>
            <year>2015</year>
            <volume>7</volume>
            <fpage>35</fpage>
            <page-range>35-47</page-range>
            <pub-id pub-id-type="pmid">25678819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stern</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Selnes</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schifitto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kieburtz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marder</surname>
                <given-names>KS</given-names>
              </name>
              <collab>Dana Consortium on the Therapy of HIV-Dementia and Related Cognitive Disorders</collab>
            </person-group>
            <article-title>Factors associated with incident human immunodeficiency virus-dementia.</article-title>
            <source>Arch Neurol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>473</fpage>
            <page-range>473-9</page-range>
            <pub-id pub-id-type="pmid">11255452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Skolasky</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Seaberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Munro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ragin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Jan</month>
            <day>26</day>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>334</fpage>
            <page-range>334-40</page-range>
            <pub-id pub-id-type="pmid">26718568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Leblanc</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corkran</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mindt</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wolfson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gamst</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fennema-Notestine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jernigan</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <collab>CHARTER Group</collab>
              <collab>HNRC Group</collab>
            </person-group>
            <article-title>HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.</article-title>
            <source>J Neurovirol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-16</page-range>
            <pub-id pub-id-type="pmid">21174240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crum-Cianflone</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poehlman Roediger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eberly</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weintrob</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ganesan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Del Rosario</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agan</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons.</article-title>
            <source>Neurology</source>
            <year>2013</year>
            <month>Jan</month>
            <day>22</day>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>371</fpage>
            <page-range>371-9</page-range>
            <pub-id pub-id-type="pmid">23303852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghafouri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khalili</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sawaya</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 associated dementia: symptoms and causes.</article-title>
            <source>Retrovirology</source>
            <year>2006</year>
            <month>May</month>
            <day>19</day>
            <volume>3</volume>
            <fpage>28</fpage>
            <pub-id pub-id-type="pmid">16712719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawrence</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Major</surname>
                <given-names>EO</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology.</article-title>
            <source>Microbes Infect</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-8</page-range>
            <pub-id pub-id-type="pmid">11909740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tucker</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aylward</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging in human immunodeficiency virus infection.</article-title>
            <source>J Neuroimmunol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>157</volume>
            <issue>1-2</issue>
            <fpage>153</fpage>
            <page-range>153-62</page-range>
            <pub-id pub-id-type="pmid">15579293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masliah</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>DeTeresa</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mallory</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Changes in pathological findings at autopsy in AIDS cases for the last 15 years.</article-title>
            <source>AIDS</source>
            <year>2000</year>
            <month>Jan</month>
            <day>07</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-74</page-range>
            <pub-id pub-id-type="pmid">10714569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Busuttil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ironside</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Rebus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Simmonds</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peutherer</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Human immunodeficiency virus and the brain: investigation of virus load and neuropathologic changes in pre-AIDS subjects.</article-title>
            <source>J Infect Dis</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>168</volume>
            <issue>4</issue>
            <fpage>818</fpage>
            <page-range>818-24</page-range>
            <pub-id pub-id-type="pmid">8376829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anthony</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas.</article-title>
            <source>Brain</source>
            <year>2003</year>
            <month>May</month>
            <volume>126</volume>
            <issue>Pt 5</issue>
            <fpage>1058</fpage>
            <page-range>1058-67</page-range>
            <pub-id pub-id-type="pmid">12690046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Multinucleated giant cells in brain: a hallmark of the acquired immune deficiency syndrome (AIDS).</article-title>
            <source>Acta Neuropathol</source>
            <year>1986</year>
            <volume>69</volume>
            <issue>3-4</issue>
            <fpage>253</fpage>
            <page-range>253-8</page-range>
            <pub-id pub-id-type="pmid">3962603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nath</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap.</article-title>
            <source>Ann Neurol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>699</fpage>
            <page-range>699-714</page-range>
            <pub-id pub-id-type="pmid">20517932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navia</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Petito</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>The AIDS dementia complex: II. Neuropathology.</article-title>
            <source>Ann Neurol</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>525</fpage>
            <page-range>525-35</page-range>
            <pub-id pub-id-type="pmid">3014994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallego</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barreiro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Ibor</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection.</article-title>
            <source>AIDS Rev</source>
            <year>2011</year>
            <season>Jul-Sep</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-9</page-range>
            <pub-id pub-id-type="pmid">21799535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <article-title>Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.</article-title>
            <source>Neurology</source>
            <year>1991</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>778</fpage>
            <page-range>778-85</page-range>
            <pub-id pub-id-type="pmid">2046917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peluso</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ferretti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boschini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gissl&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Angoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cinque</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spudich</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.</article-title>
            <source>AIDS</source>
            <year>2012</year>
            <month>Sep</month>
            <day>10</day>
            <volume>26</volume>
            <issue>14</issue>
            <fpage>1765</fpage>
            <page-range>1765-74</page-range>
            <pub-id pub-id-type="pmid">22614889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez-Valero</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Navis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.</article-title>
            <source>AIDS</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-481</page-range>
            <pub-id pub-id-type="pmid">30702516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lescure</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Moulignier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Savatovsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amiel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carcelain</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gallien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pacanovski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pialoux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Adle-Biassette</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-8</page-range>
            <pub-id pub-id-type="pmid">23515205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Changing clinical phenotypes of HIV-associated neurocognitive disorders.</article-title>
            <source>J Neurovirol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-145</page-range>
            <pub-id pub-id-type="pmid">28752495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychological assessment of HIV-infected populations in international settings.</article-title>
            <source>Neuropsychol Rev</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-49</page-range>
            <pub-id pub-id-type="pmid">19455425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thurnher</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Donovan Post</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Neuroimaging in the brain in HIV-1-infected patients.</article-title>
            <source>Neuroimaging Clin N Am</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-117; viii</page-range>
            <pub-id pub-id-type="pmid">18319157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiang</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Dutton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Aizenstein</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Toga</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry.</article-title>
            <source>Neuroimage</source>
            <year>2007</year>
            <month>Jan</month>
            <day>01</day>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-60</page-range>
            <pub-id pub-id-type="pmid">17035049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacktor</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakasujja</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Skolasky</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Selnes</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Musisi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ronald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katabira</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The International HIV Dementia Scale: a new rapid screening test for HIV dementia.</article-title>
            <source>AIDS</source>
            <year>2005</year>
            <month>Sep</month>
            <day>02</day>
            <volume>19</volume>
            <issue>13</issue>
            <fpage>1367</fpage>
            <page-range>1367-74</page-range>
            <pub-id pub-id-type="pmid">16103767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wojna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Skolasky</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hechavarr&#x000ed;a</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Selnes</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mel&#x000e9;ndez</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zorrilla</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kraiselburd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nath</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment.</article-title>
            <source>J Neurovirol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>356</fpage>
            <page-range>356-64</page-range>
            <pub-id pub-id-type="pmid">17065128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simioni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cavassini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Annoni</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rimbault Abraham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bourquin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schiffer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Calmy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chave</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Giacobini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hirschel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Du Pasquier</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.</article-title>
            <source>AIDS</source>
            <year>2010</year>
            <month>Jun</month>
            <day>01</day>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>1243</fpage>
            <page-range>1243-50</page-range>
            <pub-id pub-id-type="pmid">19996937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <collab>Mind Exchange Working Group</collab>
            <article-title>Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>1004</fpage>
            <page-range>1004-17</page-range>
            <pub-id pub-id-type="pmid">23175555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tozzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Balestra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bellagamba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corpolongo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvatori</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Visco-Comandini</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Vlassi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giulianelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galgani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antinori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narciso</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2007</year>
            <month>Jun</month>
            <day>01</day>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-82</page-range>
            <pub-id pub-id-type="pmid">17356465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marquie-Beck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Capparelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.</article-title>
            <source>Arch Neurol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-70</page-range>
            <pub-id pub-id-type="pmid">18195140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caniglia</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Cain</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Justice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tate</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sabin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Sighem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Podzamczer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arribas</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>del Romero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dabis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bucher</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Wandeler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vourli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skoutelis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gasnault</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Costagliola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;n</surname>
                <given-names>MA</given-names>
              </name>
              <collab>HIV-CAUSAL Collaboration</collab>
            </person-group>
            <article-title>Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Jul</month>
            <day>08</day>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-41</page-range>
            <pub-id pub-id-type="pmid">24907236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cysique</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cherner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.</article-title>
            <source>Neurology</source>
            <year>2009</year>
            <month>Aug</month>
            <day>04</day>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>342</fpage>
            <page-range>342-8</page-range>
            <pub-id pub-id-type="pmid">19474412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Krambrink</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Havlir</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skiest</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>A5170 Study Team</collab>
            </person-group>
            <article-title>Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.</article-title>
            <source>Neurology</source>
            <year>2010</year>
            <month>Apr</month>
            <day>20</day>
            <volume>74</volume>
            <issue>16</issue>
            <fpage>1260</fpage>
            <page-range>1260-6</page-range>
            <pub-id pub-id-type="pmid">20237308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haubrich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Umlauf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cherner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>7</issue>
            <fpage>1015</fpage>
            <page-range>1015-22</page-range>
            <pub-id pub-id-type="pmid">24352352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tozzi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Balestra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salvatori</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Vlassi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giancola</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Giulianelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narciso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antinori</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2009</year>
            <month>Sep</month>
            <day>01</day>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-63</page-range>
            <pub-id pub-id-type="pmid">19731418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabkin</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rabkin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effects of fluoxetine on mood and immune status in depressed patients with HIV illness.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1994</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>92</fpage>
            <page-range>92-7</page-range>
            <pub-id pub-id-type="pmid">7915270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perkins</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Naftolowitz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic.</article-title>
            <source>Am J Psychiatry</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>151</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-6</page-range>
            <pub-id pub-id-type="pmid">8296895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinkin</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Castellon</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Farinpour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Methylphenidate improves HIV-1-associated cognitive slowing.</article-title>
            <source>J Neuropsychiatry Clin Neurosci</source>
            <year>2001</year>
            <season>Spring</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>248</fpage>
            <page-range>248-54</page-range>
            <pub-id pub-id-type="pmid">11449032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sewell</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Jeste</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Hesselink</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chandler</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group.</article-title>
            <source>Am J Psychiatry</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>151</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-42</page-range>
            <pub-id pub-id-type="pmid">8296896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parenti</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Scheib</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Sztein</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Paxton</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>DiGioia</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Schulof</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Effect of lithium carbonate in HIV-infected patients with immune dysfunction.</article-title>
            <source>J Acquir Immune Defic Syndr (1988)</source>
            <year>1988</year>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-24</page-range>
            <pub-id pub-id-type="pmid">2975332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Worth</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Renshaw</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection.</article-title>
            <source>J Neuropsychiatry Clin Neurosci</source>
            <year>1993</year>
            <season>Fall</season>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>430</fpage>
            <page-range>430-4</page-range>
            <pub-id pub-id-type="pmid">8286943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cruess</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric manifestations of HIV infection and AIDS.</article-title>
            <source>J Psychiatry Neurosci</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>237</fpage>
            <page-range>237-46</page-range>
            <pub-id pub-id-type="pmid">16049567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guaraldi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zona</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Menozzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garlassi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roverato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palella</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Premature age-related comorbidities among HIV-infected persons compared with the general population.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>1120</fpage>
            <page-range>1120-6</page-range>
            <pub-id pub-id-type="pmid">21998278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rourke</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Murji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rourke</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Cognitive complaints, depression, medical symptoms, and their association with neuropsychological functioning in HIV infection: a structural equation model analysis.</article-title>
            <source>Neuropsychology</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>410</fpage>
            <page-range>410-9</page-range>
            <pub-id pub-id-type="pmid">12959507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shapiro</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Zingman</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Pogge</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Verghese</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Apathy correlates with cognitive performance, functional disability, and HIV RNA plasma levels in HIV-positive individuals.</article-title>
            <source>J Clin Exp Neuropsychol</source>
            <year>2013</year>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>934</fpage>
            <page-range>934-45</page-range>
            <pub-id pub-id-type="pmid">24090038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mu&#x000f1;oz-Moreno</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fumaz</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ferrer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Garc&#x000ed;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molt&#x000f3;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Negredo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clotet</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.</article-title>
            <source>AIDS Rev</source>
            <year>2009</year>
            <season>Apr-Jun</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-9</page-range>
            <pub-id pub-id-type="pmid">19529750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Casaletto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marquine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Sacktor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gamst</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Fennema-Notestine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2015</year>
            <month>Feb</month>
            <day>01</day>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>473</fpage>
            <page-range>473-80</page-range>
            <pub-id pub-id-type="pmid">25362201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radtke</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bacchetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anastos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Merenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crystal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Edmonds</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Fischl</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vance</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-208</page-range>
            <pub-id pub-id-type="pmid">29762344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbert</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Depression and immunity: a meta-analytic review.</article-title>
            <source>Psychol Bull</source>
            <year>1993</year>
            <month>May</month>
            <volume>113</volume>
            <issue>3</issue>
            <fpage>472</fpage>
            <page-range>472-86</page-range>
            <pub-id pub-id-type="pmid">8316610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farhadian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spudich</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neurological Complications of HIV Infection.</article-title>
            <source>Curr Infect Dis Rep</source>
            <year>2017</year>
            <month>Nov</month>
            <day>21</day>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">29164407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20340.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Badiee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Letendre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McCutchan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>I</given-names>
              </name>
              <collab>CHARTER Group</collab>
            </person-group>
            <article-title>CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.</article-title>
            <source>AIDS</source>
            <year>2011</year>
            <month>Sep</month>
            <day>10</day>
            <volume>25</volume>
            <issue>14</issue>
            <fpage>1747</fpage>
            <page-range>1747-51</page-range>
            <pub-id pub-id-type="pmid">21750419</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
